Last updated: October 12, 2026
TAK-788, later named mobocertinib and marketed as Exkivity, is a small-molecule EGFR tyrosine kinase inhibitor developed for metastatic non-small-cell lung cancer with EGFR exon 20 insertion mutations. The FDA granted accelerated approval in September 2021 for adults whose disease progressed after platinum-based chemotherapy. Takeda withdrew the product from the U.S. market after the confirmatory EXCLAIM-2 trial failed its progression-free-survival endpoint. The FDA withdrawal became effective on February 15, 2024. Mobocertinib no longer has a viable commercial market in the United States or a continuing global development program. [1–4]
What is the current development status of TAK-788?
Mobocertinib development has been discontinued.
The program progressed through early clinical studies, a pivotal platinum-pretreated cohort, regulatory review, and a required first-line confirmatory trial. The pivotal data supported accelerated approval in previously treated EGFR exon 20 insertion-positive metastatic NSCLC. The confirmatory study did not verify clinical benefit in the first-line setting, leading Takeda to terminate the program and withdraw approval.
| Milestone |
Date |
Status |
| Takeda acquired Ariad Pharmaceuticals, the originator of the program |
February 2017 |
Completed |
| FDA accelerated approval for Exkivity |
September 15, 2021 |
Granted |
| U.S. commercial launch |
2021 |
Completed |
| EXCLAIM-2 first-line confirmatory trial failed its primary endpoint |
2023 |
Failed |
| Takeda announced worldwide withdrawal |
October 2023 |
Announced |
| FDA withdrawal of approval became effective |
February 15, 2024 |
Completed |
| Continuing commercial development |
2024 onward |
Discontinued |
Mobocertinib is therefore no longer an active late-stage pipeline asset. Any remaining activity is limited to clinical, regulatory, or archival obligations associated with the discontinued program.
Why was mobocertinib withdrawn?
The withdrawal followed failure of the EXCLAIM-2 confirmatory trial.
The FDA’s accelerated approval was based on response data from patients with EGFR exon 20 insertion-positive NSCLC who had previously received platinum chemotherapy. Under the accelerated-approval pathway, Takeda was required to conduct a confirmatory study demonstrating clinical benefit in an earlier-line population.
EXCLAIM-2 compared mobocertinib with platinum-based chemotherapy in previously untreated patients. The trial did not demonstrate a statistically significant improvement in progression-free survival, its primary endpoint. Takeda reported that the study failed to meet the prespecified efficacy threshold. The company subsequently decided to withdraw mobocertinib globally rather than pursue additional development. [2,3]
The failure exposed a key development risk: activity in a heavily pretreated population did not translate into superior first-line performance against chemotherapy. The result also weakened the commercial rationale for maintaining a separate EGFR exon 20 insertion product in a market increasingly shaped by amivantamab and newer investigational kinase inhibitors.
What was the FDA regulatory status of TAK-788?
Exkivity had accelerated approval, not traditional approval.
The FDA approved mobocertinib for adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations whose disease had progressed on or after platinum-based chemotherapy. The approval was based on overall response rate and duration of response in a single-arm clinical development program. [1]
The original label included a limitation that continued approval could depend on confirmation of clinical benefit in a randomized trial. That requirement was not satisfied by EXCLAIM-2.
Following Takeda’s withdrawal request, the FDA formally withdrew approval of NDA 214246. After the effective withdrawal date, Exkivity was no longer an FDA-approved treatment option in the United States.
FDA status summary
| Regulatory element |
Mobocertinib status |
| Active ingredient |
Mobocertinib |
| Development code |
TAK-788 |
| Brand |
Exkivity |
| FDA pathway |
Accelerated approval |
| Initial indication |
Platinum-pretreated EGFR exon 20 insertion-positive metastatic NSCLC |
| Approval date |
September 15, 2021 |
| Confirmatory obligation |
EXCLAIM-2 |
| Confirmatory outcome |
Primary endpoint not met |
| Current U.S. approval |
Withdrawn |
| Biosimilar pathway |
Not applicable |
What was the clinical performance of mobocertinib?
Mobocertinib showed clinically relevant activity in previously treated EGFR exon 20 insertion-positive NSCLC, but its benefit was not sufficient to sustain the product after the confirmatory failure.
In the platinum-pretreated population supporting approval, the confirmed overall response rate was approximately 28%, with a median duration of response of about 17.5 months. Median progression-free survival was approximately 7.3 months, and median overall survival was approximately 24 months in the reported data set. [1,4]
The safety profile was consistent with an oral kinase inhibitor but included clinically significant gastrointestinal and cardiac toxicities. Important risks included diarrhea, rash, nausea, decreased appetite, paronychia, QT-interval prolongation, and rare serious cardiac events. The FDA label included warnings for QTc prolongation and torsades de pointes risk. [1]
Mobocertinib’s clinical positioning was limited by three factors:
- The approved setting was post-platinum treatment rather than first-line therapy.
- The product required molecular confirmation of an uncommon EGFR alteration.
- The confirmatory trial failed to establish superiority over platinum chemotherapy.
What patents protected TAK-788 and Exkivity?
Mobocertinib was protected by a combination of compound, pharmaceutical-composition, formulation, and method-of-use rights. The relevant estate originated with Ariad and transferred to Takeda through the 2017 acquisition.
The principal commercial patent issues were:
| Patent category |
Scope relevant to mobocertinib |
| Small-molecule compound patents |
Mobocertinib and related chemical structures |
| Salt and composition patents |
Pharmaceutical forms and active-ingredient compositions |
| Formulation patents |
Oral dosage forms and capsule formulations |
| Method-of-use patents |
Treatment of EGFR exon 20 insertion-positive cancers |
| Manufacturing patents |
Chemical intermediates, synthesis, and process controls |
The commercial value of this estate fell sharply after withdrawal. Patent term alone could not preserve a market for a product with no active U.S. approval and no continuing commercial strategy.
A complete patent-by-patent determination requires matching each issued patent to the relevant Orange Book listing, terminal disclaimer, pediatric exclusivity, and jurisdiction. The central business conclusion is clearer: mobocertinib’s withdrawal removed regulatory market access before patent expiry became the primary competitive issue.
What was the Orange Book status of Exkivity?
Exkivity was listed in the FDA Orange Book while its NDA was active. The product’s Orange Book relevance ended with withdrawal of NDA 214246.
The withdrawal means that future generic applicants cannot rely on an active Exkivity approval as a conventional ANDA launch target in the same way they could before the NDA withdrawal. A generic company would also face limited commercial incentive because the branded product is no longer actively marketed and the indication is narrow.
The regulatory situation differs from a standard loss-of-exclusivity event:
- The product did not remain approved until ordinary patent expiration.
- The withdrawal followed a failed accelerated-approval confirmation.
- Market entry is constrained by the absence of an active branded product and approved reference-product economics.
- Patent challenges became less important than the loss of regulatory and commercial viability.
Were there Paragraph IV challenges to mobocertinib?
No major publicly established Paragraph IV challenge became a central feature of the product’s commercial history.
The relevant generic pathway would have been an ANDA referencing an approved Exkivity NDA, supported by patent certifications. Mobocertinib’s narrow indication, short commercial life, and subsequent NDA withdrawal reduced the attractiveness of such a filing.
The principal competitive threat was not a conventional generic launch. It was clinical substitution by other EGFR exon 20 insertion-directed therapies and the failure of mobocertinib to secure a durable first-line position.
Which companies challenged or competed with TAK-788?
The principal commercial competitor was Johnson & Johnson’s amivantamab, marketed as Rybrevant.
Amivantamab received FDA approval in May 2021 for metastatic NSCLC with EGFR exon 20 insertion mutations after platinum-based chemotherapy, several months before mobocertinib. It provided the first approved targeted alternative for this molecular subgroup and competed directly with Exkivity in the post-platinum setting. [5]
| Therapy |
Company |
Modality |
EGFR exon 20 setting |
Commercial position |
| Mobocertinib |
Takeda |
Oral small-molecule TKI |
Post-platinum NSCLC |
Withdrawn |
| Amivantamab |
Johnson & Johnson |
Intravenous bispecific antibody |
Post-platinum and later-line use |
Active approved competitor during mobocertinib withdrawal |
| Poziotinib |
Spectrum Pharmaceuticals |
Oral TKI |
Investigational |
Development discontinued after regulatory setbacks |
| Zipalertinib/CLN-081 |
Cullinan Therapeutics and partners |
Oral TKI |
Investigational |
Potential next-generation competitor |
| Sunvozertinib |
Dizal |
Oral TKI |
EGFR exon 20 insertion NSCLC |
Regional development and commercialization program |
Amivantamab’s principal disadvantage relative to mobocertinib was intravenous administration and infusion-related toxicity. Mobocertinib’s advantage was oral dosing. That convenience advantage did not offset the failure of the confirmatory first-line study.
What was the commercial outlook and revenue exposure for mobocertinib?
The forward commercial outlook is effectively zero in the United States and highly limited globally because Takeda discontinued the program.
Mobocertinib entered a narrow market defined by:
- An uncommon EGFR mutation representing a small fraction of EGFR-mutated NSCLC.
- Use after platinum chemotherapy.
- Competition from an already approved antibody therapy.
- A requirement for molecular testing.
- Accelerated-approval dependence on a successful confirmatory study.
The addressable population was smaller than the broader EGFR-mutated NSCLC market. Exon 20 insertion mutations account for a small minority of EGFR alterations, and the post-platinum label further reduced eligible treatment volume.
Market projection
| Projection period |
Expected mobocertinib market condition |
| 2021–2022 |
Initial launch and uptake in post-platinum EGFR exon 20 insertion NSCLC |
| 2023 |
Major deterioration after EXCLAIM-2 failure and withdrawal announcement |
| 2024 |
U.S. approval withdrawal and commercial exit |
| 2025 onward |
No meaningful U.S. branded revenue; global availability discontinued or negligible |
A conventional peak-sales forecast is no longer decision-useful. The product’s residual value lies in intellectual property, clinical data, and possible scientific contribution to next-generation EGFR exon 20 programs, not in future branded sales.
What generic entry risks exist for mobocertinib?
The generic-entry risk is low in commercial terms but not because the product has an unusually strong surviving patent position.
Three factors reduce generic-launch risk:
- The U.S. approval was withdrawn.
- The branded market is no longer being developed.
- The eligible population is small and increasingly served by alternative targeted therapies.
A generic manufacturer could still evaluate chemical, formulation, or regulatory pathways, but the expected market would be limited. The normal strategy of waiting for patent expiry and launching against a high-revenue branded product does not apply.
How strong is the TAK-788 patent estate?
The patent estate was commercially meaningful during the approved product period but is strategically weakened by regulatory withdrawal.
Strengths
- Protection covered the active small molecule and related compositions.
- The product had differentiated activity against EGFR exon 20 insertion mutations.
- Formulation and manufacturing rights could have complicated simple copy development.
- Method-of-use claims supported the targeted NSCLC indication.
Weaknesses
- Method-of-use protection lost value after FDA withdrawal.
- A patent estate cannot substitute for an active indication and reimbursement pathway.
- Generic economic incentives were reduced by the narrow population.
- Competing products reduced the value of exclusivity even before patent expiry.
The estate may retain defensive value against unauthorized commercial use or support licensing of chemical and biological know-how. It is unlikely to support a substantial standalone revenue stream after program termination.
What licensing and transaction history affected TAK-788?
TAK-788 originated at Ariad Pharmaceuticals. Takeda acquired Ariad in 2017 for approximately $5.2 billion, bringing mobocertinib into Takeda’s oncology portfolio. [6]
The transaction gave Takeda control of the compound, development rights, clinical data, and associated intellectual property. No later licensing transaction restored the program after the EXCLAIM-2 failure and withdrawal decision.
What is the competitive outlook for EGFR exon 20 insertion NSCLC?
The market has shifted away from mobocertinib toward antibody therapy and next-generation oral inhibitors.
Amivantamab remains the primary commercial benchmark for the molecular subgroup during the period surrounding mobocertinib’s withdrawal. Investigational oral agents seek to improve selectivity, central nervous system penetration, tolerability, and first-line efficacy.
The key commercial question for future entrants is not whether they can reproduce mobocertinib’s post-platinum activity. It is whether they can demonstrate a favorable benefit-risk profile in first-line treatment and compete with platinum chemotherapy and amivantamab-based regimens.
Key Takeaways
- TAK-788 is mobocertinib, marketed as Exkivity.
- FDA accelerated approval was granted on September 15, 2021.
- The indication covered platinum-pretreated EGFR exon 20 insertion-positive metastatic NSCLC.
- EXCLAIM-2 failed to demonstrate the required first-line progression-free-survival benefit.
- Takeda withdrew the product globally.
- FDA withdrawal became effective February 15, 2024.
- Mobocertinib has no meaningful forward U.S. revenue outlook.
- The principal competitor was amivantamab, not a conventional generic.
- Patent rights retain defensive and licensing value but no longer support a major commercial franchise.
- The EGFR exon 20 market is moving toward next-generation oral inhibitors and antibody-based combinations.
FAQs About TAK-788 and Mobocertinib
Is TAK-788 still available in the United States?
No. Mobocertinib was withdrawn from the U.S. market, and FDA approval was withdrawn effective February 15, 2024.
What mutation did mobocertinib target?
Mobocertinib targeted activating EGFR exon 20 insertion mutations in non-small-cell lung cancer.
Why did mobocertinib lose FDA approval?
The required EXCLAIM-2 confirmatory trial failed to demonstrate the required progression-free-survival benefit in the first-line setting.
Is mobocertinib a biologic or a small molecule?
Mobocertinib is an orally administered small-molecule tyrosine kinase inhibitor. Biosimilar competition is therefore not applicable.
What drug replaced Exkivity in EGFR exon 20 insertion NSCLC?
Amivantamab became the principal approved alternative in the relevant treatment market. Next-generation oral inhibitors remain part of the competitive development landscape.
References
- U.S. Food and Drug Administration. (2021). Exkivity (mobocertinib) prescribing information.
- Takeda Pharmaceutical Company Limited. (2023, October 25). Takeda to withdraw mobocertinib for EGFR exon 20 insertion mutation-positive non-small cell lung cancer in the U.S.
- Takeda Pharmaceutical Company Limited. (2023). EXCLAIM-2 phase 3 trial of mobocertinib did not meet primary endpoint.
- Zhou, C., Ramalingam, S. S., Kim, T. M., et al. (2021). Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive non-small-cell lung cancer. Journal of Clinical Oncology, 39(30), 3393–3403.
- U.S. Food and Drug Administration. (2021). FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer.
- Takeda Pharmaceutical Company Limited. (2017). Takeda completes acquisition of ARIAD Pharmaceuticals.